구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Rilotumumab (Rilotumumab) SWOG Cancer Research Network·Recurrent Squamous Cell Lung Carci… 1 trials·t½ 5.6 h |
|---|---|
Overview Program | Rilotumumab |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Squamous Cell Lung Carcinoma |
Overview Indication | Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Half-life | 5.6 h |
Toxicology Major finding | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: C… |
Clinical Safety signal | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: C… |
Clinical Selected reported efficacy | ORR 21% |
Clinical Reported ORR | 21% |
Clinical Result source | ClinicalTrials.gov NCT00788957 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT00788957 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Rilotumumab (Rilotumumab) SWOG Cancer Research Network·Recurrent Squamous Cell Lung Carci… 1 trials·t½ 5.6 h |
|---|---|
Overview Program | Rilotumumab |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Squamous Cell Lung Carcinoma |
Overview Indication | Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Half-life | 5.6 h |
Toxicology Major finding | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: C… |
Clinical Safety signal | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: C… |
Clinical Selected reported efficacy | ORR 21% |
Clinical Reported ORR | 21% |
Clinical Result source | ClinicalTrials.gov NCT00788957 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT00788957 |
추천 비교
추천 비교